Slide 1: FDC Limited Investor Presentation
FDC LIMITED Investor Presentation Quarter 2 and YTD September – FY 24 www.fdcindia.com
Slide 2: Disclaimer
DISCLAIMER Except for historical information contained herein, statements in this presentation and subsequent discussions, marked by expressions like "will," "aim," "likely result," "would," "believe," "may," "expect," "continue," "anticipate," "estimate," "intend," "plan," "contemplate," "seek to,"
Slide 3: Content
Content About FDC Limited Business Highlights – Domestic and International Financial Performance – Qtr. - Sep 23 vs Sep 22 Financial Performance – YTD - Sep 23 vs Sep 22 www.fdcindia.com 3
Slide 4: FDC Limited at a Glance - Key milestones
FDC Limited at a Glance - Key milestones 1936 Established as Fairdeal Corporation by Mr. Anand Chandavarkar 1940 Incorporated Fairdeal Corporation (Private Limited) under the Indian Companies Act, 1913 1949 First formulation plant established at Jogeshwari, Mumbai in the State of Maharashtra 1963 St
Slide 5: FDC Limited at a Glance
FDC Limited at a Glance Revenue Consolidated revenue of ₹ 18 billion ($222Mn) reported for F. Y. 23 - Growth of 16.7% Key Markets India, USA, Europe, Africa and APAC – Supply to more than 40 countries Product Product ranges includes more than dozen therapeutic segment with focus on Ophthalmic, ORS,
Slide 6: FDC Limited at a Glance – Manufacturing facilities
FDC Limited at a Glance – Manufacturing facilities Location Products Regulatory Approvals Sterile ophthalmic preparations Ophthalmic facility UKMHRA approved, (7 UKMHRA inspections between 2003 and Sep 2021). Oral Liquids Cleared 6 USFDA inspections since 2005, Zero 483’s (2023), Oral Réhy
Slide 7: FDC Limited at a Glance – Manufacturing facilities
FDC Limited at a Glance – Manufacturing facilities Location Products Products Regulatory Approvals Active Pharmaceutical Ingredients (APIs) USFDA approved (APIs) WHO approved EDQM approved Roha Oral Rehydration Salt WHO, Ethiopia, Nutraceuticals - Food Plant Foods -FSSAI, BIS. Read
Slide 8: Business Highlights – Domestic
FDC Limited BUSINESS HIGHLIGHTS – DOMESTIC www.fdcindia.com 8
Slide 9: FDC Limited - Multiple Levers to drive growth
FDC Limited - Multiple Levers to drive growth FDC Overall Sales Domestic Fromulation Sales 1,778 1,445 1,300 1,523 1,336 1,323 1,061 987 1,082 896.5 836 1,021 FY19 FY20 FY21 FY22 FY23 H1FY24 FY19 FY20 FY21 FY22 FY23 H1FY24 Export Formulation Sales API Sales 270 255 223 163 134.7835 144 51.08 51 66 6
Slide 10: India (Domestic Formulation Business)
India(Domestic Formulation Business) Domestic Secondary Sales 4.8K 4,800 strong field force promoting brands 1,494 1,751 1,915 2,183 1164 FY20 FY21 FY22 FY23 H1FY24 13 Meeting with doctors every year Mn % Therapy Share 15% Anti-Infectives 5% Gastro Intestinal 9 Brands with ₹50 crs plus sales annuall
Slide 11: Top brands anchoring growth
Top brands anchoring growth Sales in INR Market Brand Molecule Rank Crs Share % ELECTRAL Oral Electrolytes ❶ 429 70.6% ZIFI Cefixime ❶ 345 25.4% ENERZAL Oral Electrolytes – Energy drink ❶ 185 49.9% ZIFI CV Cefixime+Clav. ❶ 88 49.0% VITCOFOL Iron and Other B complex Combi. (Sol+Liq+Inj) ❽ 85 2.4% ZAT
Slide 12: Electral – Category Creator and Leader in ORS
Electral – Category Creator and Leader in ORS Electral –Brand synonyms with product category In an otherwise fragmented market (Market Share) (Market Shares of Other Players) Market Share in MAT Sep 21 Market Share in MAT Sep 23 13.1% 12.4% 71.5% 70.6% 69.1% 4.0% 4.1% 3.0% 1.9% 1.5% 1.7% MAT Sep 21
Slide 13: Zifi – Category Leader in Cefixime
Zifi – Category Leader in CEFIXIME Zifi – Consistent Category Leader In an otherwise fragmented market (Market Shares of Other Players) (Market Share) Market Share in MAT Sep 21 Market Share in MAT Sep 23 22.4% 22.8% 25.4% 24.8% 24.7% 5.3% 6.3% 5.9% 6.0% 5.7% 5.1% MATSep 21 MATSep 22 MATSep 23 TAXIM
Slide 14: Enerzal – Category Leader in Energy Drinks
Enerzal– Category Leader in Energy Drinks Enerzal – Consistent Category Leader In an otherwise fragmented market (Market Share) (Market Shares of Other Players) Market Share in MAT Sep 21 Market Share in MAT Sep 23 30.2% 22.7% 49.9% 15.6% 46.3% 12.1% 44.7% 4.2% 4.0% 4.1% 2.9% MAT Sep 21 MAT Sep 22 M
Slide 15: New Launch - Adding Value
New Launch - Adding Value 1149 products have been launched in IPM in H1FY24 (Apr-Sep’23). 238 cr have been generated by these products. Zifi X was launched in Jun’23. Zifi X is N0.2 in H1 launched products, generating sales of Rs. 6.14crs Source: IQVIA-Moving Annual Total Turnover- MAT Sep 23 www.fd
Slide 16: Top 10 Fastest Growing Corporates
Top 10 Fastest Growing Corporates 3rd Fastest growing corporate as per Sep MAT’23 18.1% 14.3% 14.0% 13.9% 13.7% 12.8% 12.6% 12.0% 11.3% 10.8% 10.3% IPM C1 C2 FDC C3 C4 C5 C6 C7 C8 C9 Source: IQVIA-Moving Annual Total Turnover- MAT Sep 23 C- Competitor www.fdcindia.com 16
Slide 17: Business Highlights – International
BUSINESS HIGHLIGHTS – INTERNATIONAL www.fdcindia.com 17
Slide 18: International Formulation Business
International Formulation Business FDC holds Pride to be quality conscious with world class process driven manufacturer of formulation Export Formulation Sales FY23 - ₹254Crs 401 Product registered across 51 countries 29% 2 International offices in UK and South Africa 53% 4% 4% 8 Approved ANDAs in U
Slide 19: API Business
API Business Over the years, FDC has successfully done backward integration of many USP and CEP grade APIs ensuring consistent supply of high-quality APIs Export API Sales FY23 - ₹76crs API offering well engineered w.r.t Quality 17% 20 and economical process 44% 13% Years of Experience in maintainin
Slide 20: Financial Update – Qtr 2 and YTD Sep 23
FINANCIAL UPDATE – QTR 2 AND YTD SEP 23 www.fdcindia.com 20
Slide 21: Key Business Highlights: Qtr. 2 and YTD Sep 23
Key Business Highlights : Qtr. 2 and YTD Sep 23 Revenue mix [CATEGORY NAME] [VALUE] [CATEGORY (4%) NAME] [VALUE] (13%) Consistent growth QoQ reported both in Domestic and International business. [CATEGORY NAME] [VALUE] (83%) Domestic formulation 5.8% Export formulation 144 API in INR cr In INR cr 83
Slide 22: QoQ – Revenue and Profitability Update
QoQ –REVENUE AND PROFITABILITY UPDATE 27% 20% 11% 12% 0.5% 9% 8% 9% 342 341 495 445 409 435 536 486 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Sales (in Crs) YOY Sales Growth % 23% 16% 15% 16% 14% 12% 11% 6% 35.6 10.4 70.7 51.8 40.7 30.7 109.8 69.8 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4F
Slide 23: Financial Performance – Consolidated – Qtr. 2 Sep 23
Financial Performance – Console – Qtr. 2 SEP 23 QTR QTR Inc/(Dec) INR in cr. Sep-23 Sep-22 % Operating Revenue 486.4 445.0 9.3% COGS 169.4 161.3 5.0% Reported consistent revenue growth QoQ Operating expenses 240.6 216.3 11.2% Improved COGS and lower operating expenses leads to EBITDA 76.4 67.4 1
Slide 24: Financial Performance – Consolidated – YTD Sep 23
Financial Performance – Console – YTD SEP 23 YTD YTD Inc/(Dec) INR in cr. Sep-23 Sep-22 % Operating Revenue 1022.7 939.7 8.8% Domestic and International business continues to COGS 352.0 348.7 0.9% show strength and consistent growth in business Operating expenses 472.3 445.6 6.0% Lower COGS and
Slide 25: Thank You
THANK YOU www.fdcindia.com